izpis_h1_title_alt

AKR1B1 and AKR1B10 as prognostic biomarkers of endometrioid endometrial carcinomas
ID Hojnik, Marko (Author), ID Frković-Grazio, Snježana (Author), ID Verdenik, Ivan (Author), ID Lanišnik-Rižner, Tea (Author)

.pdfPDF - Presentation file, Download (4,19 MB)
MD5: DF1B0E9E3E55F3BC90616F471BFC7F53
URLURL - Source URL, Visit https://www.mdpi.com/2072-6694/13/14/3398 This link opens in a new window

Abstract
The roles of aldo-keto reductase family 1 member B1 (AKR1B1) and B10 (AKR1B10) in the pathogenesis of many cancers have been widely reported but only briefly studied in endometrial cancer. To clarify the potential of AKR1B1 and AKR1B10 as tissue biomarkers of endometrial cancer, we evaluated the immunohistochemical levels of AKR1B1 and AKR1B10 in tissue paraffin sections from 101 well-characterized patients with endometrioid endometrial cancer and 12 patients with serous endometrial cancer and compared them with the clinicopathological data. Significantly higher immunohistochemical levels of AKR1B1 and AKR1B10 were found in adjacent non-neoplastic endometrial tissue compared to endometrioid endometrial cancer. A trend for better survival was observed in patients with higher immunohistochemical AKR1B1 and AKR1B10 levels. However, no statistically significant differences in overall survival or disease-free survival were observed when AKR1B1 or AKR1B10 were examined individually in endometrioid endometrial cancer. However, analysis of AKR1B1 and AKR1B10 together revealed significantly better overall and disease-free survival in patients with both AKR1B1 and AKR1B10 staining above the median values compared to all other patients. Multivariant Cox analysis identified strong AKR1B1 and AKR1B10 staining as a statistically important survival prediction factor. Conversely, no significant differences were found in serous endometrial cancer. Our results suggest that AKR1B1 and AKR1B10 play protective roles in endometrioid endometrial cancer and show potential as prognostic biomarkers.

Language:English
Keywords:endometrial carcinoma, survival, immunohistochemistry, prognosis, biomarker, aldo-keto reductase family 1 member B1 (AKR1B1), aldo-keto reductase family 1 member B10 (AKR1B10)
Work type:Article
Typology:1.01 - Original Scientific Article
Organization:MF - Faculty of Medicine
Publication status:Published
Publication version:Version of Record
Year:2021
Number of pages:14 str.
Numbering:Vol. 13, iss. 14, art. 3398
PID:20.500.12556/RUL-135595 This link opens in a new window
UDC:616-006
ISSN on article:2072-6694
DOI:10.3390/cancers13143398 This link opens in a new window
COBISS.SI-ID:69972739 This link opens in a new window
Publication date in RUL:21.03.2022
Views:1115
Downloads:137
Metadata:XML DC-XML DC-RDF
:
Copy citation
Share:Bookmark and Share

Record is a part of a journal

Title:Cancers
Shortened title:Cancers
Publisher:MDPI
ISSN:2072-6694
COBISS.SI-ID:517914137 This link opens in a new window

Licences

License:CC BY 4.0, Creative Commons Attribution 4.0 International
Link:http://creativecommons.org/licenses/by/4.0/
Description:This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.
Licensing start date:07.07.2021

Secondary language

Language:Slovenian
Keywords:karcinom endometrija, preživetje, imunohistokemija

Projects

Funder:ARRS - Slovenian Research Agency
Project number:J3-8212
Name:Vloga intrakrinega delovanja estrogenov pri hormonsko odvisnih boleznih – pomen za zdravljenje

Funder:ARRS - Slovenian Research Agency
Project number:J3-2535
Name:Vloga androgenov pri hormonsko odvisnih boleznih: pomen za diagnostiko in zdravljenje

Funder:ARRS - Slovenian Research Agency
Funding programme:Young researchers

Similar documents

Similar works from RUL:
Similar works from other Slovenian collections:

Back